ClinicalTrials.gg
RecruitingNCT07728994Updated Jul 27, 2026

SONATA LIFU for OCD

A Phase 2 interventional study of Low Intensity Focused Ultrasound and Sham (No Treatment) in Obsessive Compulsive Disorder, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by University of Pennsylvania · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
22 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 299 studies in Obsessive-Compulsive Disorder with a site in United States — 59 open to participants now, 77 under way, 2 of them phase 3. Obsessive-Compulsive Disorder · United States.

Planned enrollment
122nd of 246
40 · median 40
Started
2026
with 12 others
Phase 2
46 of 299
6 open now
Primary completion
2028-07
later than 50 of 76 live
Registered
296th of 299
by date

Among the 299 studies in Obsessive-Compulsive Disorder with a site in United States, this one is the 122nd largest by planned enrollment of the 246 interventional ones that give a count, is one of 13 that started in 2026, is one of 46 in phase 2, reaches primary completion later than 50 of the 76 other live ones, and was the 296th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

59 of the 299 studies in Obsessive-Compulsive Disorder with a site in United States are open now. Recruiting first, the newest first:

53 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 22 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Obsessive-Compulsive Disorder with a site in United States, or all of them as a file.
02

Study summary

The study tests ATTN201, an investigational non-invasive headband that delivers low-intensity focused ultrasound (LIFU) to the subthalamic nucleus (STN) as a treatment for obsessive-compulsive disorder (OCD). It's a randomized, double-blind, 1:1 (active: sham) study with 40 total participants spanning 12-16 weeks and 14 in-person and remote visits.

Read the detailed description

This is a randomized, double-blind, sham-controlled study evaluating the safety and feasibility of ATTN201, an investigational, non-invasive, wearable ultrasound headband, in adults with obsessive-compulsive disorder (OCD). ATTN201 uses low-intensity focused ultrasound (LIFU), guided by magnetic resonance imaging (MRI), to deliver stimulation to the subthalamic nucleus (STN), a brain region implicated in OCD symptom circuits. This is the fifth study in which ATTN201 has been used in humans, and the device is not currently approved by the U.S. Food and Drug Administration (FDA) for clinical use outside of research.

Approximately 40 participants will be enrolled in this study, ages 18-80, will be enrolled at a single site in San Francisco. Participants will be randomly assigned in a 1:1 ratio to receive either active focused ultrasound stimulation (20 participants) or sham (inactive) stimulation (20 participants). Sham stimulation sounds the same as active stimulation but does not deliver a therapeutic ultrasound effect to the brain. Neither participants nor the study staff administering treatment will know which group a participant has been assigned to during the treatment period.

Participation lasts approximately 12 to 16 weeks and includes 14 in-person and remote visits.

03

Conditions studied

  • Obsessive Compulsive Disorder

Keywords

  • OCD
  • LIFU
04

Who can participate

Ages eligible
22 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a principal diagnosis of OCD according to the with duration of > 1 year
  2. Have a Y-BOCS of > 16
  3. Participants currently on OCD medication must be at the same stable dose(s) for at least 3 weeks prior to screening and throughout the course of the study, and must continue to be under the care of their treating psychiatrist through the duration of the study.
  4. Be between 22 to 80 years of age (inclusive) on the day of signing .
  5. Be able and willing to undergo a cranial MRI
  6. Be able and willing to wear an Attune device throughout the experimental sessions.
  7. Sign the informed consent form, in accordance with local requirements, after the scope and nature of the investigation have been explained to the subject, and before screening assessments.
  8. Be able to speak, read, and understand the language of the trial staff and the informed consent form.
  9. Possess the ability to respond verbally to questions, follow instructions, and complete study assessments.
  10. Be able to adhere to the stimulation protocol and visit schedules.
  11. Be determined by the investigator to be medically stable at baseline/randomization as assessed by medical history and non-significant clinical results of a vital signs examination.
  12. Male participants must ensure a condom is used for all sexual intercourse and follow acceptable methods of for their female partner for the entire duration of the study. Male participants should not father a child or donate sperm for this same period.
  13. Female participants who are sexually active agree to use two methods of contraception for the duration of the study or not be of as indicated by one of the following:

    1. Has reached natural menopause, defined as 45 years of age with ≥6 months of spontaneous amenorrhea
    2. Has had a hysterectomy;
    3. Has had bilateral tubal ligation; or
    4. Has had a bilateral oophorectomy (with or without a hysterectomy) and greater than 6 weeks have passed since the surgery

Exclusion criteria

Exclusion Criteria:

  1. Has a current or prior history of bipolar I or II disorder, schizophrenia or other psychotic disorder, borderline personality disorder, Tourette's disorder
  2. Has acute suicidality or suicide attempt or self-injurious behavior in the last 6 months
  3. Has a history of deep brain stimulation or ablative surgery
  4. Has a history of substance abuse including alcohol use disorder in the past 6 months (except for caffeine and nicotine)
  5. Has a history of traumatic brain injury with loss of consciousness, seizures,or other neurological disorders.
  6. Has any for completing a brain MRI scan.

    a. The subject's head must fit within the head coil (32 or 64 channel), while wearing the MR-compatible device.

  7. Has had a ketamine or TMS treatment within the last month prior to recruitment.
  8. Has had any medical or psychiatric symptoms or conditions that could interfere with study activities or confound interpretation of study results.
  9. Has a recent or ongoing, uncontrolled, medical condition where participation in the trial would pose a significant medical risk to the subject or would confound study results within 3 months of Screening, such as:

    1. Conditions including but not limited to diabetes, hypertension, (HIV) or other relevant infections, thyroid or endocrine disease, (COPD), delirium, congestive heart failure, angina, cardiac or gastrointestinal disease, or renal disease requiring dialysis, or unstable .
    2. Major surgery including not limited to abdominal, thoracic, cardiac, or orthopedic surgery, or any procedure requiring general anesthesia.
    3. Subjects with recently controlled or treated medical conditions may be considered for re-screening on a case-by-case basis after consultation with the Sponsor.
    4. Has a history of hepatitis or liver disease that, in the opinion of the investigator, has been active within the 6 months prior to Visit 1.
  10. Is pregnant, is attempting to become pregnant, or is nursing children.
  11. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an site or sponsor staff directly involved with this trial.
  12. Has a (BMI) >34 kg/m2. BMI is calculated by taking the subject's weight in kg and dividing by the subject's height in meters, squared
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active Stimulation

    ATTN201 focused ultrasound stimulation delivered to the subthalamic nucleus (STN)

    Device: Low Intensity Focused Ultrasound

  • Sham comparator
    Sham Stimulation

    ATTN201 sham/unfocused stimulation - device is fitted and produces the same audible sound as active stimulation but delivers no substantive focused ultrasound effect to the brain.

    Device: Sham (No Treatment)

Interventions

  • DeviceLow Intensity Focused Ultrasound

    ATTN201 is an investigational, non-invasive, wearable headband containing two ultrasound transducers positioned over the temporal region of the skull. Guided by a pre-treatment MRI, the device delivers focused low-intensity ultrasound (LIFU) to the subthalamic nucleus (STN).

    Also known as: LIFU

  • DeviceSham (No Treatment)

    Participants are fitted with the same ATTN201 headband used in the active arm, and the device is operated using the same procedures and audible output as active stimulation. However, the ultrasound is unfocused and does not deliver a therapeutic effect to the brain. This sham condition is designed to be indistinguishable from active stimulation to preserve blinding of participants and study staff.

06

What researchers measure

Primary outcomes

  1. Change in OCD symptom severity

    Measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

    Time frame: up to 3 months

  2. Incidence and severity of adverse events

    Device-related and procedure-related side effects

    Time frame: up to 3 months

Secondary outcomes

  1. Change in Anxiety Symptoms

    Beck Anxiety Inventory

    Time frame: up to 3 months

  2. Change in depressive symptoms

    Beck Depression Inventory - II (BDI-II)

    Time frame: up to 3 months

  3. Change in global impression

    Clinical global impression severity and clinical global impression improvement

    Time frame: up to 3 months

  4. Change in functional disability

    Sheehan Disability Scale

    Time frame: up to 3 months

  5. session-level symptom change

    Visual Analog Scale ratings collected at each study intervention session

    Time frame: up to 3 months

  6. Change in resting-state and task based functional connectivity

    fMRI

    Time frame: up to 3 months

07

Study locations

1 of 1 sites recruiting
  • Attune Neurosciences
    San Francisco, California 94107, United States
    Recruiting
    • Lena Kozyr · Contact
    • Katherine Scangos, MD, PhD · Principal investigator
08

References and documents

Publications

  • Aubry JF, Attali D, Schafer ME, Fouragnan E, Caskey CF, Chen R, Darmani G, Bubrick EJ, Sallet J, Butler CR, Stagg CJ, Klein-Flugge MC, Yoo SS, Holland CK, Treeby B, Martin E, Verhagen L, Butts Pauly K. ITRUSST consensus on biophysical safety for transcranial ultrasound stimulation. Brain Stimul. 2025 Nov-Dec;18(6):1896-1905. doi: 10.1016/j.brs.2025.10.007. Epub 2025 Oct 8. PubMed 41072763 ↗
  • Stern JM, Spivak NM, Becerra SA, Kuhn TP, Korb AS, Kronemyer D, Khanlou N, Reyes SD, Monti MM, Schnakers C, Walshaw P, Keselman I, Cohen MS, Yong W, Fried I, Jordan SE, Schafer ME, Engel J Jr, Bystritsky A. Safety of focused ultrasound neuromodulation in humans with temporal lobe epilepsy. Brain Stimul. 2021 Jul-Aug;14(4):1022-1031. doi: 10.1016/j.brs.2021.06.003. Epub 2021 Jun 23. PubMed 34198105 ↗
  • Munoz F, Meaney A, Gross A, Liu K, Pouliopoulos AN, Liu D, Konofagou EE, Ferrera VP. Long term study of motivational and cognitive effects of low-intensity focused ultrasound neuromodulation in the dorsal striatum of nonhuman primates. Brain Stimul. 2022 Mar-Apr;15(2):360-372. doi: 10.1016/j.brs.2022.01.014. Epub 2022 Jan 29. PubMed 35092823 ↗
  • Gaur P, Casey KM, Kubanek J, Li N, Mohammadjavadi M, Saenz Y, Glover GH, Bouley DM, Pauly KB. Histologic safety of transcranial focused ultrasound neuromodulation and magnetic resonance acoustic radiation force imaging in rhesus macaques and sheep. Brain Stimul. 2020 May-Jun;13(3):804-814. doi: 10.1016/j.brs.2020.02.017. Epub 2020 Feb 21. PubMed 32289711 ↗
  • Darmani G, Bergmann TO, Butts Pauly K, Caskey CF, de Lecea L, Fomenko A, Fouragnan E, Legon W, Murphy KR, Nandi T, Phipps MA, Pinton G, Ramezanpour H, Sallet J, Yaakub SN, Yoo SS, Chen R. Non-invasive transcranial ultrasound stimulation for neuromodulation. Clin Neurophysiol. 2022 Mar;135:51-73. doi: 10.1016/j.clinph.2021.12.010. Epub 2021 Dec 31. PubMed 35033772 ↗
  • Blackmore J, Shrivastava S, Sallet J, Butler CR, Cleveland RO. Ultrasound Neuromodulation: A Review of Results, Mechanisms and Safety. Ultrasound Med Biol. 2019 Jul;45(7):1509-1536. doi: 10.1016/j.ultrasmedbio.2018.12.015. Epub 2019 May 18. PubMed 31109842 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 27, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Oct 31, 2028
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07728994
Collaborators
Attune Neurosciences Inc
Responsible party
Katherine Scangos (Associate Professor of Psychiatry, University of Pennsylvania) — Principal investigator
First posted
Jul 27, 2026
Start date
Jul 1, 2026
Primary completion
Jul 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Jul 27, 2026

Study contacts

Giovanna Rocchio
Contact
giovanna.rocchio@pennmedicine.upenn.edu
6177657150

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion